BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22147262)

  • 1. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
    Tiedemann RE; Zhu YX; Schmidt J; Shi CX; Sereduk C; Yin H; Mousses S; Stewart AK
    Cancer Res; 2012 Feb; 72(3):757-68. PubMed ID: 22147262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.
    Gong JN; Khong T; Segal D; Yao Y; Riffkin CD; Garnier JM; Khaw SL; Lessene G; Spencer A; Herold MJ; Roberts AW; Huang DCS
    Blood; 2016 Oct; 128(14):1834-1844. PubMed ID: 27465916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
    Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
    Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
    Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
    Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
    Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
    Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
    [No Abstract]   [Full Text] [Related]  

  • 6. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
    Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
    Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma.
    Crawford LJ; Anderson G; Johnston CK; Irvine AE
    Oncotarget; 2016 Oct; 7(43):70481-70493. PubMed ID: 27655696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
    Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
    Cell Death Dis; 2014 Feb; 5(2):e1072. PubMed ID: 24556687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
    Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
    Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
    Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
    Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
    Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
    Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
    Soncini D; Martinuzzi C; Becherini P; Gelli E; Ruberti S; Todoerti K; Mastracci L; Contini P; Cagnetta A; Laudisi A; Guolo F; Minetto P; Miglino M; Aquino S; Varaldo R; Reverberi D; Formica M; Passalacqua M; Nencioni A; Neri A; Samur MK; Munshi NC; Fulciniti M; Lemoli RM; Cea M
    Haematologica; 2022 Jun; 107(6):1410-1426. PubMed ID: 34670358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.
    Ruiz-Vela A; Aggarwal M; de la Cueva P; Treda C; Herreros B; Martín-Pérez D; Dominguez O; Piris MA
    Blood; 2008 Feb; 111(3):1665-76. PubMed ID: 18032706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.